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Several clinical conditions may precipitate acute heart failure (AHF) and influence clinical outcome. In 
this study we hypothesized that precipitating factors are independently associated with 90-day risk of 
death in AHF. 
 
Methods and results 
The study population consisted of 15’828 AHF patients from Europe and Asia. The primary outcome 
was 90-day all-cause mortality according to identified precipitating factors of AHF (acute coronary 
syndrome, infection, atrial fibrillation, hypertension and non-compliance). Mortality at 90 days was 
15.8%.  
AHF precipitated by acute coronary syndrome (ACS) or by infection showed increased 90-day risk of 
death compared to AHF without identified precipitants (HR 1.69 [95% CI 1.44-1.97], P<0.001 and HR 
1.51 [95% CI 1.18-1.92], P=0.001), while AHF precipitated by atrial fibrillation showed lower 90-day 
risk of death (HR 0.56 [95% CI 0.42-0.75], P<0.001), after multivariable adjustment. 
The risk of death in AHF precipitated by ACS was the highest during the first week after admission, 
while in AHF precipitated by infection the risk of death had a delayed peak at week 3. In AHF 
precipitated by atrial fibrillation a trend toward reduced risk of death all along the first weeks was 
shown. At weeks 5 to 6, AHF precipitated by ACS, infection or atrial fibrillation showed similar risk of 
death to that of AHF without identified precipitants. 
 
Conclusions 
Precipitating factors are independently associated with 90-day mortality in AHF. AHF precipitated by 
acute coronary syndrome or infection is independently associated with higher, while AHF precipitated 
by atrial fibrillation is associated with lower 90-day risk of death. 
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Despite major achievements in the treatment of chronic heart failure (CHF) with marked improvement 
in survival, the management of acute heart failure (AHF) remains challenging 1. One possible 
explanation of the persistently high mortality in AHF is its phenotypic heterogeneity. AHF is a 
syndrome defined by changes in symptoms and/or signs of heart failure (HF), rather than a specific 
disease 2. Several conditions are recognized to precipitate AHF, including acute coronary syndrome, 
atrial fibrillation, infections, uncontrolled arterial hypertension, and lack of compliance with dietary and 
drug prescriptions 3.  
 
Current recommendations for the management of HF advise identification of precipitants of AHF in 
order to specifically treat the cause(s) of the acute episode (e.g. revascularization for acute coronary 
syndrome, antiarrhythmic treatment for atrial fibrillation, antimicrobial drugs for infections) 1,4. In 
marked contrast, decisions about intensity of monitoring and therapy (e.g. patient allocation in normal 
ward or intensive care unit) are rather based on haemodynamic parameters and/or biomarkers with 
little regard to the underlying precipitants 1,4. 
 
It is still matter of debate whether ascertaining precipitating factors of AHF identify patients at 
particularly high risk of unfavourable outcome in need of more intensive monitoring and therapy. It is 
equally unknown whether specific precipitants independently affect outcome of AHF patients 3,5. The 
aim of the present study was to test the hypothesis that precipitating factors of AHF independently 





Study population and outcome 
The study population is derived from the GREAT registry, an international, prospective observational 
cohort of 20’598 adult patients with AHF as main diagnosis of hospital admission. Details on the 
constitution of the GREAT registry have been previously described 6. AHF - both new-onset HF and 
acutely decompensated HF - was defined according to the definition of the European Society of 
Cardiology 4. 4’770 patients (23%) included in GREAT were excluded from the present analysis 
because they were missing data on vital status during 90 days after admission or precipitating factors 
of AHF. The study population was composed of 15’828 AHF patients from 7 countries in Europe 
(Czech Republic, Italy, Spain) and in Asia (China, Japan, Saudi Arabia, South Korea), Figure 1.  
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The primary outcome of the study was 90-day all-cause mortality. Six distinct classes of precipitating 
factors were considered: acute coronary syndrome, infection, atrial fibrillation, hypertension, non-
compliance, and no identified precipitating factor. Patients were assigned to one or more precipitating 
factors by treating physicians according to the initial clinical presentation.  
Following definitions were used: “ACS” in presence of ECG alterations and/or dynamic elevation of 
standard troponin levels, according to the criteria of the European Society of Cardiology 7,8; “infection” 
in presence of fever and/or other evidence of infection at presentation (leucocytosis, elevated 
inflammatory parameters, clinical or microbiological evidence of infection); “atrial fibrillation” in 
presence of atrial fibrillation (new-onset or recurrent) with ventricular response > 110/min, 
“hypertension” in presence of elevated systolic blood pressure (>160 mmHg) at presentation and “non-




Values are expressed as median (interquartile range, IQR) or as number (percentage), as appropriate. 
Group characteristics were compared with the Chi-square test or the Kruskal-Wallis test, as 
appropriate. Survival was plotted with the Kaplan-Meier curve and differences between groups were 
assessed by the log-rank test, with pairwise comparisons if indicated. Univariate and covariate-
adjusted Cox proportional hazards regression models were used to estimate the association between 
the presence of precipitating factors and the 90-day risk of death compared to absence of identified 
precipitating factors. Data of patients with more than one precipitating factor were analysed separately. 
 
The covariates included in the regression models were a priori selected among baseline variables with 
known associations with study outcomes 6: age, gender, LVEF, comorbidities (history of heart failure, 
coronary artery disease, diabetes), systolic blood pressure, heart rate, eGFR and plasma sodium at 
admission. The AHEAD score, based on age (≥70 years), history of atrial fibrillation, history of 
diabetes, anaemia (haemoglobin <120 g/L in women, <130 g/L in men), renal dysfunction (creatinine ≥ 
130 µmol/L), was used to estimate the burden of comorbidities 9. When these data were missing, 
case-wise deletion for that analysis only was used. 
 
We conducted exploratory analyses of the variation in relative hazards of death among those still alive 
in the cohort by time since admission. Because there was no literature upon which to base a priori 
decisions about functional forms, we used a maximally flexible approach to letting the hazard ratios 
vary over time. We divided the cohort into 7 time periods, balancing roughly even numbers of events 
without being completely arbitrary: weekly for the first 4 weeks, then biweekly for the next 4 weeks, 
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then combining the remaining weeks of the cohort, and estimated separate hazard ratios for each time 
period. Because this was an exploratory analysis that could be interpreted in support of several 
different questions, no adjustment for multiple comparisons were done—as each of the different 
questions implies different numbers of comparisons—but instead standard confidence intervals are 
reported and interpreted cautiously. 
 
The null hypothesis was rejected with an adjusted two-sided p-value < 0.05. All analyses were 






The study population consisted of a cohort of 15’828 AHF patients from 7 countries (Figure 1). The 
median age was 71 years and 58% were men. Medical history reported high prevalence of coronary 
artery disease (49%), cardiovascular risk factors (hypertension 66%, diabetes 43%) and comorbidities 
(65% of patients had a AHEAD score of 2 or more points). At admission, 46% of patients reported 
previous history of heart failure; median LVEF was 38%; median BNP and NT-proBNP were 866 and 
3823 ng/L, respectively. In patients with previous history of heart failure, 14% were in NYHA class I, 
27% in NYHA class II, 40% in NYHA class III and 19% in NYHA class IV. Ten percent of patients were 
in cardiogenic shock. Other baseline characteristics of the study population are reported in Table 1. 
 
Precipitating factors of AHF 
Precipitating factors of AHF were identified in 8’784 patients (55%), while in 7’044 patients (45%) no 
specific precipitant could be identified. One single precipitant was identified in 7’764 patients (49% of 
the study population) while in 1’020 patients (6% of the study population) a combination of two or more 
precipitants were identified. 
 
Among the 7’764 patients with one single identified precipitant, acute coronary syndrome (ACS) was 
the most common cause (n=4’004, 52%), followed by atrial fibrillation (n=1’228, 16%), infection 
(n=1’104, 14%), uncontrolled hypertension (n=831, 11%) and non-compliance (n=597, 8%). 
Cardiogenic shock was more frequent in patients with ACS (13%) compared to patients with infection 
(6%) and non-compliance (5%), p<0.001. Notable differences in baseline characteristics between the 
groups of precipitating factors were present (Table 1). Of note, elevated plasma troponin 
concentrations were found in 66% of patients for whom measurement at hospital admission was 
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available (n=8’061). In patients with ACS as precipitating cause, elevated troponin was found in 71% 
of patients.  
 
Precipitating factors and 90-day mortality 
Figure 2 shows that among patients with only one identified precipitant, every precipitating factor was 
associated with strikingly different 90-day mortalities (log-rank P<0.001). Notably, Figure 2 shows that 
compared to patients without identified precipitants, patients admitted with AHF precipitated by ACS or 
by infection showed higher 90-day hazard of death (ACS: HR 1.51 [95% CI 1.38-1.66], P<0.001 and 
infection: HR 1.40 [95% CI 1.21-1.62], P<0.001, respectively). On the other end of the spectrum, 
patients with AHF precipitated by uncontrolled hypertension or atrial fibrillation showed reduced 90-
day hazard of death compared to patients without identified precipitant (HR 0.56 [95% CI 0.44-0.72], 
P<0.001 and HR 0.72 [95% CI 0.60-0.86], P<0.001, respectively). The group of patients with AHF 
precipitated by non-compliance showed an intermediate hazard of death, similar to those of patients 
without identified precipitant (HR 0.96 [95% CI 0.77-1.21], P=0.74). 
 
After adjustment for 10 a priori-selected prognostic determinants (age, gender, LVEF, history of heart 
failure, coronary artery disease and diabetes, systolic blood pressure and heart rate at admission, 
renal function and plasma sodium at admission), AHF precipitated by ACS or by infection showed 
persistent increased 90-day hazard of death compared to AHF without identified precipitants (HR 1.69 
[95% CI 1.44-1.97], P<0.001 and HR 1.51 [95% CI 1.18-1.92], P=0.001). Furthermore, AHF 
precipitated by atrial fibrillation showed lower 90-day risk of death compared to AHF without identified 
precipitants (HR 0.56 [95% CI 0.42-0.75], P<0.001), Figure 3. The reduced risk of death associated 
with hypertension as precipitating factor lost statistical significance after covariate adjustment. 
Of note, AHF with more than one identified precipitating factor showed similar outcome overall to AHF 
with only one precipitating factor (Supplementary Figure, log-rank P=0.67).  
Subgroup analysis according to World area are reported in Supplementary Table. AHF precipitated by 
ACS was associated with increased 90-day hazard of death in both European and Asian populations, 
while AHF precipitated by infection was associated with particularly bad prognosis in Asians. 
 
 
Patterns of the risk of death during the first weeks after admission 
The risk of death associated with different precipitating factors, compared to the absence of identified 
precipitants, was not homogeneous during the first weeks after admission. As shown in an exploratory 
analysis in Figure 4, the relative hazard of death in AHF precipitated by ACS was the highest during 
the first week after admission (HR 2.57 [95% CI 2.22-2.99], P<0.001), while in AHF precipitated by 
infection a delayed peak of the relative hazard of death was shown at week 3 (HR 2.83 [95% CI 1.95-
This article is protected by copyright. All rights reserved.
 8 
4.12], P<0.001). Conversely, in AHF precipitated by atrial fibrillation possible reduced risk of death all 
along the first weeks after admission was shown - but that difference was not statistically significant. 
Notably, at weeks 5 to 6 and thereafter, AHF precipitated by ACS, infection or atrial fibrillation showed 
similar risk of death to that of AHF without identified precipitants (HR 0.93 [95% CI 0.69-1.26], P=0.64, 
HR 0.91 [95% CI 0.55-1.51], P=0.72 and HR 0.90 [95% CI 0.57-1.43], P=0.66, respectively for weeks 
5-6).  
 
Patients with high burden of comorbidities (AHEAD score ≥ 4 points) showed increased risk of death 
compared to patients with less comorbidities (AHEAD score < 4 points) all along the first weeks after 
admission. However, as depicted in Figure 4, while the association between precipitating factors and 
risk of death decreased in strength with time since admission, the association between comorbidities 
and increased risk of death became closer from week 1 (HR 1.48 [95% CI 1.24-1.76], P<0.001) to 





Ascertainment of precipitating factors is recommended by current AHF guidelines and, as shown by 
the present study, allows stratification of 90-day risk of death 1,4. This study, using a large, 
intercontinental registry, extends the previously described finding of the North-American OPTIMIZE-
HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) 
registry and substantially extends the concept to the European and Asian AHF populations 3. 
Furthermore, our study, by adjusting for several clinical confounders, shows the independent 
association of ACS or infection with higher aggregate hazard of death and atrial fibrillation with lower 
hazard of death—and our exploratory analyses suggest that those relative hazards vary with time 
since admission in non-trivial ways. 
 
In our large cohort, ACS was shown to be the most common precipitant of AHF, as previously shown 
in the OPTIMIZE-HF and in the French EFICA (Etude Française de l’Insuffisance Cardiaque Aiguë) 
registries 3,10. Previous data showed that ACS complicated by AHF carries particularly high risk of 
adverse outcome 11,12 and, similarly, AHF caused by ACS is associated with the highest risk of short-
term death, as confirmed by our study 3,13,14. The unfavourable association between AHF and 
(ischemic) myocardial injury is further supported by the analyses of the ADHERE (Acute 
Decompensated Heart Failure National Registry) study, which reported a marked association between 
elevated cardiac troponin levels and increased risk of death in AHF 15. Our study clearly showed that, 
when ACS precipitates AHF, the risk of death is highest only transiently, during the first week after 
This article is protected by copyright. All rights reserved.
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admission. There is now an urgent need to test whether this early, high risk of death might be reduced 
through optimal revascularization and/or medical therapy 16. Timely revascularization might reduce the 
burden of AHF in ACS patients 17. A survival benefit of revascularization was shown in the subgroup of 
AHF patients with cardiogenic shock complicating ACS, but evidence in the larger group of AHF 
patients without shock is less clear 18.  
 
The present study also showed high 90-day risk of death when infection precipitated AHF. The 
generalizability of these results is supported by very recent data from a three-centre registry, showing 
increased mortality in patients with AHF precipitated by acute pulmonary disease (mostly pneumonia 
or COPD exacerbation) 5. Moreover, the association of AHF and other non-cardiac acute illness is 
particularly unfavourable 19. In the present study, the risk of death was maximal during week 3 after 
admission, though infection was already recorded at admission for AHF. The delay between hospital 
admission and death supports the concept of a complex interaction between infection and a 
combination of endothelial dysfunction, plaque instability, activated coagulation 20, volume overload, 
inflammatory and ischemic myocardial injury 21 and arrhythmias 22, and risk for precipitating other non-
cardiac illnesses which may lead to death 23. It is also possible, however, that this delayed peak may 
result from a direct focus on the management of the AHF and a relative neglect of the implied sepsis, 
potentially with suboptimal antibiotic management by clinicians focused on the heart. The interplay 
between intrinsic physiology and clinician behaviour warrants further study, as infection-triggered AHF 
is quite common in our cohort and others. 
 
Conversely, our study showed relatively low risk of death when atrial fibrillation precipitated AHF. 
These observations are in line with those of the Spanish PAPRICA-2 (PApel pronostico de los 
PRecipitantes de un episodio de Insuficiencia Cardiaca Aguda) study, which showed relatively 
favourable short-term outcome in AHF precipitated by atrial fibrillation 13. However, other studies 
previously described an association between atrial fibrillation, in particular new-onset forms, and 
increased risk of both short- and long-term mortality in AHF 24,25. Very recent data showed an 
association between atrial fibrillation and higher risk of readmission in AHF 26. New-onset atrial 
fibrillation, through loss of atrial contraction and/or high ventricular rate, may rapidly deteriorate the 
haemodynamic status and induce AHF even in patients with less severe structural cardiac 
abnormalities and without major changes in volaemia 27. However, appropriate antiarrhythmic 
treatment may rapidly restore haemodynamics without need for intensive treatment with vasodilators 
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The present study has notable limitations. Variables included in the survival models were selected 
among independent predictors of mortality, as previously described in detail 6. As in any observational 
study, hidden unmeasured variables might interfere with the results. Nonetheless, random assignment 
to alternative triggers of AHF is infeasible, and the clinical implication of the study—that ascertainment 
of precipitating factors may distinguish different risk profiles in AHF—remains prognostically relevant 
although we have not proven causation. Several differences in the use of oral HF medications at 
admission were observed. However, the impact of chronic treatment on short-term outcome of AHF 
patients is less pronounced compared to treatment after admission 28. We further acknowledge that 
treatment after admission (including information about coronary revascularization, antimicrobial drugs 
and antiarrhythmic therapy) is not reported in our registry and that notable differences around the 
World may exist 29,30. However, since recruiting centers are tertiary hospitals with high level of 
experience in treating AHF, the observed association between precipitating factors and different 
outcomes might have been smoothened rather than sharpened. 
Moreover, non-compliance to drug and/or dietary recommendation may be larger than reported and 
may have been substantially influenced by heterogeneity in cultural habits in different continents.  
In addition, the rather large group of patients without identified precipitant may include patients with 
other unrecorded precipitants or may reflect the diagnostic challenge of identifying precipitants of AHF. 
Substantial differences may exist between patients with different forms of AHF. However, our cohort 





Precipitating factors substantially influence 90-day mortality of AHF patients. In particular, AHF 
precipitated by ACS or infection is independently associated with higher, while AHF precipitated by 
atrial fibrillation is associated with lower 90-day risk of death. Both these facts, and their time-varying 
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Tables and Figures 
 
Table 1. Baseline characteristics of the study population 
 
 Total One precipitating factor Combined factors No factors P-value 
 n=15’828 n=7’764 n=1’020 n=7’044  
  ACS Infection Atrial fibrillation Hypertension Non-compliance    
  n=4’004 n=1’104 n=1’228 n=831 n=597    
Age [years] 71 [61-80] 72 [62-79] 72 [60-81] 73 [62-81] 73 [62-80] 67 [54-76] 66 [56-75] 72 [61-80] <0.001 
Male gender 58% 63% 53% 52% 47% 67% 61% 56% <0.001 
BMI [kg/m2] 26.1 [23-29.9] 26.1 [23.4-29.3] 24.6 [21.8-28.6] 26.6 [23.5-30.7] 27.7 [24.4-32.5] 27.9 [24.2-32.1] 27.6 [24-31.8] 25.7 [22.6-29.5] <0.001 
Hypertension 66% 67% 64% 62% 89% 60% 78% 62% <0.001 
Diabetes 43% 49% 38% 33% 47% 48% 66% 38% <0.001 
Coronary artery disease 49% 87% 40% 18% 27% 47% 64% 34% <0.001 
Heart failure 46% 25% 55% 43% 38% 83% 61% 54% <0.001 
Atrial fibrillation 30% 15% 37% 68% 22% 32% 22% 33% <0.001 
COPD 16% 11% 19% 18% 19% 14% 8% 19% <0.001 
Systolic BP [mmHg] 130 [110-150] 130 [110-150] 127 [110-145] 130 [113-150] 180 [158-200] 119 [104-136] 135 [110-160] 130 [110-150] <0.001 
Diastolic BP [mmHg] 79 [65-90] 75 [62-85] 73 [62-84] 80 [70-90] 95 [80-110] 70 [60-80] 76 [65-90] 80 [66-90] <0.001 
Heart rate [bpm] 88 [73-105] 88 [73-101] 86 [74-100] 114 [86-135] 90 [75-107] 84 [70-97] 90 [78-106] 85 [72-102] <0.001 
LVEF [%] 38 [27-50] 37 [30-46] 40 [30-55] 44 [30-55] 50 [45-60] 33 [25-42] 40 [30-52] 35 [25-50] <0.001 
Haemoglobin [g/L] 128 [111-142] 130 [113-144] 121 [106-139] 132 [117-144] 127 [111-141] 125 [110-140] 122 [106-139] 128 [112-142] <0.001 
Sodium [mmol/L] 138 [135-141] 138 [135-141] 138 [134-141] 139 [136-141] 139 [136-142] 137 [133-140] 136 [133-139] 139 [136-141] <0.001 
Potassium [mmol/L] 4.1 [3.9-4.6] 4 [3.8-4.5] 4.2 [4-4.7] 4.1 [4-4.6] 4.1 [3.9-4.6] 4.2 [3.9-4.7] 4.1 [3.8-4.6] 4.2 [3.9-4.7] <0.001 
eGFR [ml/min] 54 [38-71] 54 [38-70] 58 [39-80] 57 [43-73] 55 [40-70] 54 [42-71] 51 [36-72] 53 [38-70] <0.001 
Glucose [mmol/L] 7.5 [5.9-10.9] 9 [6.7-13] 7.1 [5.6-9.6] 7 [5.8-9.5] 8.2 [6.1-11.6] 7.3 [5.7-10.1] 8.4 [6.1-12.4] 7 [5.6-9.7] <0.001 
BNP [ng/L] 866 [376-1682] 940 [422-1677] 1007 [463-1665] 591 [336-1362] 1089 [319-2192] 1420 [808-3338] 869 [523-2240] 843 [367-1660] 0.01 
NTproBNP [ng/L] 3823 [1656-8454] 3992 [1428-11018] 3450 [1634-7728] 4406 [2311-8398] 3119 [1344-8871] 5108 [2943-8449] 5370 [2269-9387] 3628 [1575-7941] 0.001 
Troponin I [µg/L] 0.05 [0.016-0.2] 0.265 [0.06-3.28] 0.027 [0.01-0.09] 0.05 [0.02-0.161] 0.05 [0.01-0.19] 0.05 [0.02-0.19] 0.145 [0.05-0.83] 0.03 [0.01-0.092] <0.001 
Betablocker 40% 42% 39% 34% 43% 67% 72% 32% <0.001 
ACEi or ARB 61% 58% 56% 58% 67% 71% 70% 60% <0.001 
Diuretic 59% 41% 70% 55% 54% 72% 55% 68% <0.001 
Nitrate 18% 23% 13% 12% 20% 22% 23% 16% <0.001 
Aspirin 44% 48% 27% 33% 43% 61% 69% 40% <0.001 
Statin 34% 33% 23% 24% 33% 53% 60% 31% <0.001 
 
Legend: P-values refer to global comparisons between patients without or with single precipitating factors. ACEi angiotensin-converting enzyme inhibitor, ACS acute coronary syndrome, ARB 
angiotensin receptor blocker, BP blood pressure, COPD chronic obstructive pulmonary disease, eGFR estimated glomerular filtration rate, LVEF left-ventricular ejection fraction 
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Figure 1. Flowchart of the study population 
 
Legend: The study population consisted of a cohort of 15’828 AHF patients for which information on precipitating factors of AHF 





Figure 2. Ninety-day survival according to the presence of identified precipitating factors of 
acute heart failure 
 
Legend: Difference in 90-day survival according to the presence of identified precipitating factors of AHF was found (overall log-
rank P <0.001). Pairwise comparisons with patients without identified precipitating factors showed lower survival in patients with 
acute coronary syndrome or infection as precipitants of AHF (adjusted log-rank P <0.001 for both), and increased survival in 
patients with atrial fibrillation or hypertension as precipitants of AHF (adjusted log-rank P=0.004 and P<0.001, respectively). No 





Figure 3. Precipitating factors and 90-day risk of death 
 
Legend: Risk of 90-day mortality expressed as hazard ratio (HR) and 95% confidence interval (CI) in presence of precipitating 
factors of AHF compared with absence of identified precipitating factors. Adjustment was performed for age, gender, history of 
heart failure, coronary artery disease, diabetes, systolic blood pressure at admission, heart rate at admission, LVEF, eGFR at 





Figure 4. Time-course of risk of death according to precipitating factors and burden of 
comorbidities 
 
Legend: The weekly risk of death associated with the presence of selected precipitating factors of AHF (red: acute coronary 
syndrome; orange: infection; blue: atrial fibrillation) compared with absence of identified precipitating factors is expressed as 
hazard ratio (HR) and 95% confidence interval (CI). The weekly risk of death associated with the presence of multiple 
comorbidities (AHEAD score ≥ 4 points) compared to score < 4 points is depicted in grey 
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